11-Jun-2010 | research and development
Aeterna Zentaris Reports Final Results of a Phase 2 Study of Perifosine in the Treatment of Colorectal Cancer
Aeterna Zentaris Inc. reported final results on the clinical activity of perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral ...